X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (85) 85
female (75) 75
male (75) 75
oncology (74) 74
index medicus (72) 72
aged (71) 71
lung neoplasms - drug therapy (61) 61
middle aged (56) 56
carcinoma, non-small-cell lung - drug therapy (47) 47
chemotherapy (46) 46
adult (36) 36
lung cancer (36) 36
aged, 80 and over (34) 34
antineoplastic combined chemotherapy protocols - therapeutic use (32) 32
non-small cell lung cancer (31) 31
lung cancer, non-small cell (27) 27
lung neoplasms - mortality (27) 27
lung neoplasms - pathology (26) 26
cancer (25) 25
docetaxel (24) 24
treatment outcome (24) 24
cisplatin (23) 23
carcinoma, non-small-cell lung - mortality (22) 22
care and treatment (21) 21
carboplatin (19) 19
carcinoma, non-small-cell lung - pathology (19) 19
disease-free survival (19) 19
neoplasm staging (19) 19
survival (19) 19
mutation (18) 18
nivolumab (18) 18
respiratory system (18) 18
carboplatin - administration & dosage (17) 17
gefitinib (17) 17
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
lung neoplasms - genetics (16) 16
trial (16) 16
antineoplastic agents - therapeutic use (15) 15
hematology, oncology and palliative medicine (15) 15
prognosis (15) 15
carcinoma, non-small-cell lung - genetics (13) 13
patients (13) 13
pulmonary/respiratory (13) 13
research (13) 13
survival rate (13) 13
antineoplastic agents - adverse effects (12) 12
cisplatin - administration & dosage (12) 12
drug administration schedule (12) 12
kaplan-meier estimate (12) 12
medicine & public health (12) 12
non-small cell lung carcinoma (12) 12
retrospective studies (12) 12
combination (11) 11
gemcitabine (11) 11
japan (11) 11
lung cancer, small cell (11) 11
medicine, general & internal (11) 11
metastasis (11) 11
paclitaxel (11) 11
receptor, epidermal growth factor - genetics (11) 11
safety (11) 11
analysis (10) 10
bevacizumab (10) 10
cancer therapies (10) 10
clinical trials (10) 10
erlotinib (10) 10
non-small-cell lung cancer (10) 10
open-label (10) 10
tumors (10) 10
disease progression (9) 9
nsclc (9) 9
1st-line treatment (8) 8
adenocarcinoma (8) 8
adenocarcinoma - drug therapy (8) 8
carcinoma (8) 8
carcinoma, squamous cell - drug therapy (8) 8
egfr mutation (8) 8
etoposide (8) 8
multicenter (8) 8
paclitaxel - administration & dosage (8) 8
survival analysis (8) 8
tegafur - administration & dosage (8) 8
vinorelbine (8) 8
antineoplastic agents - administration & dosage (7) 7
apoptosis (7) 7
drug combinations (7) 7
health aspects (7) 7
lung neoplasms - radiotherapy (7) 7
medical prognosis (7) 7
metaanalysis (7) 7
oncology, experimental (7) 7
original (7) 7
oxonic acid - administration & dosage (7) 7
product development (7) 7
quinazolines - administration & dosage (7) 7
studies (7) 7
acquired-resistance (6) 6
antibodies, monoclonal - adverse effects (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 990 - 998
Summary Background Optimum management strategies for patients with advanced non-small-cell lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase... 
Hematology, Oncology and Palliative Medicine | TYROSINE KINASE INHIBITORS | MULTICENTER | ONCOLOGY | ADENOCARCINOMA | ACQUIRED-RESISTANCE | OPEN-LABEL | AFATINIB | ERLOTINIB | GEMCITABINE | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Glutamates - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Infusions, Intravenous | Mutation | Guanine - administration & dosage | Medical colleges | Chemotherapy | Strategic planning (Business) | Genetic aspects | Product development | Lung cancer, Non-small cell | Gefitinib | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1236 - 1244
Summary Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR mutation-positive non-small-cell lung cancer... 
Hematology, Oncology and Palliative Medicine | TRIAL | GROWTH-FACTOR RECEPTOR | CISPLATIN PLUS GEMCITABINE | PLACEBO | EFFICACY | NSCLC | ONCOLOGY | ADENOCARCINOMA | DOUBLE-BLIND | COMBINATION | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Confidence Intervals | Prognosis | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Male | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Squamous Cell - mortality | Neoplasm Invasiveness - pathology | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Development and progression | Care and treatment | Cross infection | Nosocomial infections | Erlotinib | Lung cancer, Non-small cell
Journal Article
Journal Article
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 07/2019, Volume 14, Issue 7, pp. 1119 - 1121
Journal Article
Cancer Science, ISSN 1347-9032, 05/2017, Volume 108, Issue 5, pp. 1000 - 1006
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 8/2016, Volume 24, Issue 8, pp. 3495 - 3505
Journal Article
SCIENTIFIC REPORTS, ISSN 2045-2322, 12/2019, Volume 9, Issue 1, pp. 1 - 11
To investigate the exposure-safety relationships of afatinib in Japanese population, we performed population pharmacokinetics (PK) analysis of afatinib in... 
1ST-LINE TREATMENT | GEFITINIB EFFICACY | ADENOCARCINOMA | MULTIDISCIPLINARY SCIENCES | PHASE-II | OPEN-LABEL | ERBB FAMILY BLOCKER | ERLOTINIB
Journal Article
World Journal of Clinical Oncology, ISSN 2218-4333, 10/2014, Volume 5, Issue 4, pp. 646 - 659
First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib and erlotinib, have proven to be highly effective... 
Epidermal growth factor receptor tyrosine kinase inhibitors | Secondary resistance | Epidermal growth factor receptor mutation | Non-small cell lung cancer | Topic Highlight
Journal Article
ANTICANCER RESEARCH, ISSN 0250-7005, 07/2019, Volume 39, Issue 7, pp. 3923 - 3929
Background/Aim: Treatment with EGFR-tyrosine kinase inhibitor (TKI) shows a durable response against NSCLC harboring EGFR mutation; however, treatment... 
1ST-LINE TREATMENT | GEFITINIB | MULTICENTER | SENSITIVITY | T790M | OPEN-LABEL | CHEMOTHERAPY | EGFR mutation | CELL LUNG-CANCER | EVOLUTION | Afatinib | ONCOLOGY | sequential TKI-therapy | osimertinib | MUTATION | INHIBITORS | Tyrosine | Heterogeneity | Epidermal growth factor receptors | Non-small cell lung carcinoma | Mutation | Gefitinib | Kinases | Patients | Protein-tyrosine kinase
Journal Article
Journal Article
by Garassino, Marina Chiara and Cho, Byoung-Chul and Kim, Dong-Wan and Kim, Joo-Hang and Kim, Sang-We and Kim, Young-Chul and Mazières, Julien and Vansteenkiste, Johan and Lena, Hervé and Corral Jaime, Jesus and Gray, Jhanelle E and Powderly, John and Chouaid, Christos and Bidoli, Paolo and Wheatley-Price, Paul and Park, Keunchil and Soo, Ross A and Huang, Yifan and Wadsworth, Catherine and Dennis, Phillip A and Rizvi, Naiyer A and Paz-Ares Rodriguez, Luis and Novello, Silvia and Hiret, Sandrine and Schmid, Peter and Laack, Eckart and Califano, Raffaele and Maemondo, Makoto and Chaft, Jamie and Vicente Baz, David and Berghmans, Thierry and Surmont, Veerle and Reck, Martin and Han, Ji-Youn and Holgado Martin, Esther and Belda Iniesta, Cristobal and Oe, Yuichiro and Chella, Antonio and Chopra, Akhil and Robinet, Gilles and Soto Parra, Hector and Thomas, Michael and Cheema, Parneet and Katakami, Nobuyuki and Su, Wu-Chou and Wolf, Juergen and Lee, Jong-Seok and Saka, Hideo and Milella, Michele and Ramos Garcia, Inmaculada and Sibille, Anne and Yokoi, Takashi and Kang, Eun Joo and Atagi, Shinji and Spaeth-Schwalbe, Ernst and Nishio, Makoto and Imamura, Fumio and Gabrail, Nashat and Veillon, Remi and Derijcke, Sofie and Maeda, Tadashi and Zylla, Dylan and Kubiak, Kendra and Santoro, Armando and Uy, Ma. Noemi and Lucien Geater, Sarayut and Italiano, Antoine and Kowalski, Dariusz and Barlesi, Fabrice and Chen, Yuh-Min and Spigel, David and Chewaskulyong, Busyamas and Garcia Gomez, Ramon and